The Department of Health in Abu Dhabi along with Rafed, the UAE’s primary group for the supply chain of essential medical equipment, has announced that Abu Dhabi has received the AstraZeneca medication.
The medication has been approved for local use to prevent severe infection and death in non-vaccinated high-risk patients.
The UAE is one of the first countries to receive antibody medication for immunocompromised patients.
His Excellency Dr Jamal Mohammed Al Kaabi, Undersecretary of the Department of Health in Abu Dhabi said, “The UAE continues to exhibit unprecedented leadership, with Abu Dhabi at its core when it comes to a human-centred COVID-19 response. The public-private partnership behind AZD7442, the world’s first long-acting antibody with Phase III data demonstrating benefit in both prophylaxis and treatment of COVID-19, is yet another example of the UAE’s successful pandemic response thus far. When approved, this medication will help immunocompromised patients who could not receive the vaccine due to medical reasons and limiting autoimmune disorders. The UAE will continue to act as a catalyst for change by leveraging collaborations, both regionally and internationally.”